Arcutis Biotherapeutics (ARQT) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.06
- Estimate
- $0.17
- Surprise
- -64.4%
- Revenue (period 2026-09-30)
- $143.9M
- Score at report (before → after)
- 6.5 → 6.4/10
Revenue source: xbrl.
How the report landed
Arcutis Biotherapeutics (ARQT) missed the $0.17 estimate with adjusted EPS of $0.06 — a large 64.4% shortfall. TrendMatrix's engine moved from Hold (6.5/10) to Sell at 6.4/10 after the report.
Coverage in the report window
- Why AppLovin Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket — benzinga, 2026-11-05
Where TrendMatrix's rating stands now
TrendMatrix currently rates ARQT Sell at 6.4/10.
2 of the last 4 quarters beat the estimate; this quarter's -64.4% surprise compares with a +11.8% four-quarter average.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong growth profile
What argues against it
- Concentration risk — Product: ZORYVE franchise
- Concentration risk — Supplier: AstraZeneca
- Analyst target reached - limited upside remaining
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $34.05
- Stop
- $31.67
The stock trades at 154.8× trailing but 25.4× forward earnings — consensus estimates already build in a substantial earnings recovery.
Risk check: RSI 71 — a level conventionally read as overbought; gains at these levels often lean on momentum.
Model outputs from TrendMatrix’s engine as of 2026-11-05 — shown for context, not personalized investment advice.
ARQT at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $4.28B
- P/E (fwd)
- 25.4
- P/E (ttm)
- 154.8
- 52-week range
- $19.30–$34.80
- Off 52-week high
- 2.2%
- RSI (14)
- 71
- Volume vs avg
- 1.19×
- Score today
- 6.4/10